Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial Pneumonia
COLUMBUS, Ohio – November 30, 2022 – Clarametyx Biosciences Inc.…
Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101
COLUMBUS, Ohio – October 5, 2022 – Clarametyx Biosciences Inc. (“Clarametyx”),…
CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial Infections
Supplemental award extends CARB-X collaboration as the Company advances toward…
Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial Infections
Technology prevents development of bacterial biofilms to allow for rapid…
New Publication in Cell Implicates a Rare Form of DNA Driving Antimicrobial Resistance in Bacterial Biofilms
Critical new insights suggest Z-DNA could represent a novel therapeutic target…
Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial Infections
Award expands development resources following completion of $8 million…
Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael Layman
Mr. Layman joins as an independent director as the company continues to…
Clarametyx featured in 2021 Technology Showcase, hosted by Nationwide Children’s Hospital’s Office of Technology Commercialization
Clarametyx Chief Scientific Officer Chuck McOsker participated in the 2021 NCH…
David Richards Appointed CEO of Clarametyx Biosciences
Company also expands Board of Directors with the appointment of Larry Edwards…
Newly Published Insights in Biofilm Illustrate the Powerful Mechanisms of an Antibody Biofilm Eradication Therapy Approach
Biofilms represent a substantial challenge to treating bacterial infections,…